Rigel Pharmaceuticals
RIGL
159 hedge funds and large institutions have $614M invested in Rigel Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
25% more capital invested
Capital invested by funds: $493M → $614M (+$121M)
5% more funds holding
Funds holding: 152 → 159 (+7)
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
0.16% less ownership
Funds ownership: 8.48% → 8.32% (-0.16%)
5% less call options, than puts
Call options by funds: $3.43M | Put options by funds: $3.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.39M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.66M |
| 3 |
Millennium Management
New York
|
+$3.59M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.28M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.2M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$7.36M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.89M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.39M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.97M |
RIGL Hedge Fund Activity: Q2 2021 in Review
159 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2021, worth a combined $614M — up 25% from $493M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RIGL positions and 17 closed out — a net gain of 8 holders — while 48 added to existing stakes and 47 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $8.39M. The largest seller was Citadel Advisors, cutting an estimated $12.2M.
- 159 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2021, up from 152 in Q1 2021.
- Funds reported $614M of Rigel Pharmaceuticals stock for Q2 2021, up 25% quarter-over-quarter.
- 25 funds opened new Rigel Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +8 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2021 was Candriam SCA, an estimated $8.39M added.
- The largest Rigel Pharmaceuticals seller in Q2 2021 was Citadel Advisors, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2021.